沙库必曲/缬沙坦 T2318

Product Introduction
Bioactivity


英文名: Sacubitril/Valsartan

描述: Sacubitril/Valsartan (LCZ696)，以1:1摩尔比由Valsartan（一种ARB）和Sacubitril（AHU377）组成，为创新口服血管紧张素受体-脑啡肽酶（ARN）双重抑制剂，旨在治疗高血压与心力衰竭。其作用机制包括抑制炎症、氧化应激及细胞凋亡，有助于改善糖尿病心肌病。

体外活性: LCZ696 is a single molecule that is comprised of molecular moieties of valsartan, an ARB, and AHU377, a neprilysin inhibitor (1:1 ratio)[1].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: Ethanol : 9 mg/mL (9.82 mM)
H2O : 92 mg/mL (100.4 mM)
DMSO : 45.45 mg/mL (47.45 mM)


关键字: hypertension | Angiotensin Receptor | orally | Cluster of differentiation 10 | angiotensin | Neprilysin | receptor-neprilysin | NEP | Neutral endopeptidase | inhibit | ARN | LCZ-696 | CD10 | heart | Inhibitor | LCZ 696 | Apoptosis | Sacubitril/Valsartan

相关产品: Caudatin | Ecdysone | ASK1-IN-2 | Nirogacestat | Chelerythrine chloride | α-Lipoic Acid | MT 63-78 | 4-MMPB | Pitstop 2 | MARK4 inhibitor 1

相关库: Drug Repurposing Compound Library | Anti-Neurodegenerative Disease Compound Library | Anti-Cancer Drug Library | Clinical Compound Library | Membrane Protein-targeted Compound Library | Anti-Metabolism Disease Compound Library | Inhibitor Library | Anti-Cancer Clinical Compound Library | Anti-Cancer Approved Drug Library | Endocrinology-Hormone Compound Library

沙库必曲/缬沙坦 T2318信息由TargetMol中国为您提供，如您想了解更多关于沙库必曲/缬沙坦 T2318报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途